Therapeutic antibodies for COVID-19
Eli Lilly and Company received foundation support to facilitate access to future Lilly therapeutic antibodies under development for the prevention and treatment of COVID-19 in low- and middle-income countries as part of the COVID-19 Therapeutics Accelerator. The antibodies will be manufactured at FUJIFILM Diosynth Biotechnologies facility in Denmark.
- Focus areas
- Healthcare Delivery
- Investment type
- Volume guarantee
- Status
- Exit
- Initial investment
- Public
- Partnered in
- 2020
- Headquarters
- USA
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.